Lincy Shiny Marino G’s scientific contributions

What is this page?


This page lists works of an author who doesn't have a ResearchGate profile or hasn't added the works to their profile yet. It is automatically generated from public (personal) data to further our legitimate goal of comprehensive and accurate scientific recordkeeping. If you are this author and want this page removed, please let us know.

Publications (1)


Figure 8: Colony formation analysis between drug treated colonies and EVs treated colonies.
Figure 9: AO EtBr staining of HCT 116 cell line; (A) -Control, (B)-Cells with MSC -EVs, (C) -Cells with Eugenol primed MSC -EVs.
Results of the scratch assay -rate of proliferation (%).
Assessment of anti-cancer activity of human umbilical cord tissue-derived Eugenol primed mesenchymal stem cells-extracellular vesicles
  • Article
  • Full-text available

January 2024

·

25 Reads

Journal of Applied Biology & Biotechnology

Lincy Shiny Marino G

·

Nithya Gnanasekaran Thirumullaivoyal

·

·

[...]

·

Praveen Kumar L

Colorectal cancer (CRC) is on the rise, with existing treatment modules showing little therapeutic success. Earlier studies have shown that the alteration of the tumor microenvironment was made possible by the secretory factors of mesenchymal stem cells (MSCs) which include extracellular vesicles (EVs), certain chemokines, cytokines, and other metabolites. MSC-EVs tend to mimic their parental cells, which possess characteristics like pro-tumor and anti-tumor effects. As conventional cancer treatments have shown adverse effects like anticancer drug resistance, the need for the use of natural products is a recent topic of interest. Eugenol, an active component of S. aromaticum, is known for its antioxidant, anti-inflammatory, and anti-cancer properties. This study focuses on the priming of Eugenol with the human umbilical cord tissue (hUCT) MSC derived EVs as an alternate therapeutic option to treat colorectal cancer, followed by EVs characterization. Finally, the anti-cancer activity of the formulated EVs was assessed by in vitro studies on colon cancer cells. The in vitro anticancer assay showed a significant reduction in the proliferation of cells when treated with Eugenol primed EVs. Thus, the anti-cancer potential of the Eugenol primed EVs was validated, which can be looked upon as a suitable alternative to a cell-free therapeutic option for treating CRC.

Download